1 / 47

First Annual NHLBI Community Forum on Data Standards and Terminology INTERMACS: A Study in Collaboration Among Federa

. I will not discuss off label use and/or investigational use of the following drugs/devices in my presentation:I do not have any relationship(s) to disclose.. Interagency Registry for Mechanically Assisted Circulatory SupportNHLBI Contract

lyle
Télécharger la présentation

First Annual NHLBI Community Forum on Data Standards and Terminology INTERMACS: A Study in Collaboration Among Federa

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    27. Adverse Event Collection Adverse Events: Data on specific adverse events will be collected by two mechanisms: (1) The occurrence of infection, device failure, neurological event, and death trigger a separate screen which will collect relevant data elements; (2) Other adverse events will be identified and collected through routine data acquisition at the specified follow-up intervals

    31. Relevance to FDA (and therefore Industry) Standardized adverse event definitions Manufacturers and user facilities must fulfill their own specific reporting requirements and this can occur through their participation in INTERMACS FDA letters to user facilities exempt them from MDR reporting if they participate in INTERMACS; however devices not collected by INTERMACS must follow current MDR reporting process INTERMACS data will be helpful for manufacturers as they develop other clinical trial designs

More Related